• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
WANG Tongjin,ZHANG Yanhang,LU Juan,CHAI Ruiping,CHEN Xi.Research on the functional mechanism of Shengmai Injection based on network pharmacology[J].Journal Of Pharmaceutical Research,2018,37(11):621-624[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 7719times   Download 7224次 QR Code for this article
Scan with your phone!
基于网络药理学的生脉注射液作用机制研究
王同瑾1,张晏航2,路娟1,柴瑞平1,陈曦1
Font:Larger+|Default|Smaller-
(1.中国医学科学院、北京协和医学院药用植物研究所,北京 100193;2.佳木斯市第一中学,黑龙江 佳木斯 154003)
摘要:
目的 基于网络药理学技术探索生脉注射液的体内药效物质基础和作用机制。方法 通过数据库及文献检索方法获取生脉注射液的有效成分,通过BATMAN-TCM构建的分子对接技术预测生脉注射液有效成分的体内作用靶标及相关通路,基于京都基因与基因组百科全书(KEGG)的通路富集分析功能,阐述生脉注射液的多成分-多通路作用机制。结果 通过上述方法共计发现295个有效成分,直接或间接涉及体内4 891个靶标,552种相关疾病。关键成分是,锦葵酸、腺苷、蝙蝠葛碱、维生素B12、十四醇、腺苷三磷酸肌醇。关键靶标是亚当金属肽酶结构域8、AKT丝氨酸/苏氨酸激酶1、ATP结合盒亚家族成员1、花生四烯酸15脂肪氧化酶、腺苷A1受体、缓激肽受体B2、一氧化氮合酶3、乙酰胆碱酯酶、丁酰胆碱酯酶。关键疾病是炎症反应、乳腺癌、心血管疾病、前列腺癌、哮喘、脓毒症、动脉粥样硬化、帕金森氏病、阿尔兹海默病、精神分裂症。涉及通路是糖酵解/糖异生、柠檬酸循环、磷酸戊糖途径、戊糖和葡糖醛酸盐相互转化、果糖与甘露糖代谢、半乳糖代谢、抗坏血酸与醛酸代谢、脂肪酸生物合成、脂肪酸伸长、脂肪酸降解。结论 生脉注射液主要通过多成分协同起效的机制起到抗炎、抗乳腺癌等疾病的作用。本研究结果初步验证了生脉注射液治疗疾病的有效成分和作用机制,为进一步深入揭示相关疾病的有效治疗方法开发奠定基础。
关键词:  网络药理学  生脉注射液  炎症反应  靶点  通路
DOI:10.13506/j.cnki.jpr.2018.11.001
基金项目:国家自然科学基金面上项目(No.81673667)
Research on the functional mechanism of Shengmai Injection based on network pharmacology
WANG Tongjin1,ZHANG Yanhang2,LU Juan1,CHAI Ruiping1,CHEN Xi1
(1.The Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100193,China;2.Jiamusi No.1 High School,Jiamusi 154003,China)
Abstract:
Objective To explore the pharmacodynamic basis and mechanism of Shengmai injection in vivo based on network pharmacology. Methods The effective components of Shengmai Injection were obtained by database and literature search. The target of Shengmai Injection in vivo and It's related pathways were predicted by BATMAN-TCM molecular docking technique. Based on the pathway enrichment analysis function of Kyoto Encyclopedia Gene and Genome (KEGG), the Shengmai Injection was expounded with the mechanism of multicomponent-multichannel action. Results A total of 295 active ingredients were found by the above methods, which directly or indirectly involved 4 891 targets and 552 related diseases in vivo. The key ingredients were malolate, adenosine, dauricine, vitamin B12, tetradecanol and inositol adenosine triphosphate. The key targets were Adam metallopeptidase domain 8, AKT serine/threonine kinase 1, ATP binding cassette subfamily 1, arachidonate 15 lipase oxidase, adenosine A1 receptor, bradykinin receptor B2, nitric oxide synthase 3, acetylcholinesterase, and butyrylcholinesterase. The key diseases were inflammation, breast cancer, cardiovascular disease, prostate cancer, asthma, sepsis, atherosclerosis, Parkinson's disease, Alzheimer's disease, schizophrenia. The pathways involved were glycolysis/gluconeogenesis, citric acid cycle, pentose phosphate pathway, pentose and glucuronate conversion, fructose and mannose metabolism, galactose metabolism, ascorbic acid and aldehyde metabolism, fatty acid biosynthesis, fatty acid elongation, and fatty acid degradation.Conclusion Shengmai Injection played an anti-inflammatory and anti-breast cancer role mainly through the mechanism of multi-component synergy. The results of this study preliminarily verified the effective components and mechanism of Shengmai Injection, and laid a foundation for further revealing the effective treatment of related diseases.
Key words:  Network pharmacology  Shengmai Injection  Inflammatory reaction  Target  Pathway
Today's Visits:438    Total Visits:2383115
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.